Baird analyst Michael Ha lowered the firm’s price target on Universal Health (UHS) to $203 from $243 and keeps a Neutral rating on the shares. The firm adjusted the price target after updating its power rankings in managed care and healthcare facilities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health Services Faces Revenue Uncertainty Amid Medicaid Dependence and State-Level Risks
- Universal Health’s Strong Financial Performance and Future Growth Potential Justify Buy Rating
- Cantor maintains Neutral rating on Universal Health
- Universal Health price target raised to $259 from $257 at Barclays
- Universal Health Services Reports Strong Q2 2025 Results